For a drug that everything in RA has been built on, we're not great at predicting who will respond to methotrexate. It's probably because we don't have all the info. Adding pharmacogenomics increased optimal AI prediction from 55% to 76% @MayoClinic FRI0046 #EULAR2020 @RheumNow https://t.co/bwpSYQIBLG

Filgo reduces PsA markers OP0224. ? Unique to filgo, a JAK1 effect , class effect or part of any effective PsA Rx or some of the above? @eular_org @RheumNow @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/2O5wsLPNl2

• https://twitter.com/DrPetryna/status/1269006416569827331

I've heard people say FDG uptake on PET/CT in PMR/GCA is just a correlate of systemic inflamm. Look at the uptake intensity (SUVmax) vs inflamm markers in n=65 PET/CT in GCA. There's no pattern whatsoever. Not just an expensive ESR! @FreemanHospital SAT0272 #EULAR2020 @RheumNow https://t.co/D4xAZC7KmO

In this unprecedented time, I must thank #EULAR2020 and @RheumNow for keeping all of us focused on the future. It’s inspiring and I needed the reminder! @KDAO2011 @CCalabreseDO @drdavidliew @DrPetryna @philipcrobinson @LCalabreseDO @RonanTKavanagh

To truly address adherence, you need to understand what is impairing it, and tailor an approach to overcome those barriers. Great to see this articulated in EULAR recommendations re: non-adherence - a big factor in our therapeutic outcomes! EULAR projects #EULAR2020 @RheumNow https://t.co/0pazcDFTuV

Is there subclinical GCA in PMR pts? 50 consecutive PMR pts had vascular USS. 27/50 had GCA vascular uptake, of which 10 had no GCA symptoms at all. Is PMR sometimes just the tip of the GCA iceberg? Do the aSx USS+ pts get GCA Sx eventually? Bonn SAT0254 #EULAR2020 @RheumNow https://t.co/UmsixY29Qh

#EULAR2020 OP0019 DON'T STOP TNFi in RA remission per ARCTIC-REWIND trial: RCT X 1 year n=99 multicenter gov't funded- DAS28 remission X1 year, dz X10 yrs, 2/3 pts (RF+/CCP+), no doppler signal. Results: 63% flared who had TNFi w/drawn vs. 5% when TNFi continued @RheumNow https://t.co/SsR1vUGbOe

Analysis of the UK THIN database shows that delays in receiving followup Denosumab injx results in higher fracture risk (vertebral & Maj OP Fx). 6144 infusions in 2594 pts, shows risk if delay is >16wks (long delay), but not if 4-16wks #EULAR20 SAT0453 https://t.co/DkJK3dHeRN https://t.co/r7ckpSF6PA

• https://bit.ly/2z6UhnA

H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in Pain, FACIT, Boolean remission); But UPA has more serious AE (vs ABA) - esp hepatic, OI, SIE, SAE, CPK (but not zoster VTE) #EULAR20 SAT0151 https://t.co/K96lybdg7L https://t.co/vQM2MSCNzD

• https://bit.ly/3eXAaYu

Dr Mariette summarizes the evidence for using cytokine-targeted therapies in #COVIDー19 Several studies with favorable results with #Tocilizumab and #Anakinra, however, almost all with methodological limitations (e.g., historical groups) #EULAR2020 #EULAR20 #EULAR2020goesvirtual https://t.co/cMUKoeGfK9